I have a masters degree in Analytics from Northwestern University and a bachelors degree in Accounting. I have worked in the investment arena for over 10 years starting as an analyst and working my way up to a management role. Dividend investing is a personal hobby and I look forward to sharing my thoughts with the Seeking Alpha community.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a pu ...

Core Insights - Balchem Plant Nutrition has launched the Metalosate T.E.A.M.™ digital platform to assist specialty crop advisors in optimizing nutrient balance, enhancing yield potential, and improving crop quality while minimizing input costs [1][5]. Group 1: Product Overview - The T.E.A.M. platform stands for Technical Evaluation of Albion Minerals and is based on decades of Balchem's research, utilizing plant tissue analysis to evaluate nutrient concentrations against optimal crop-specific ranges [2]. - T.E.A.M. simplifies the interpretation of complex plant tissue analysis results, providing actionable micronutrient recommendations rather than just data points [3]. Group 2: Benefits and Impact - Field trials indicate that T.E.A.M.-guided programs have led to measurable improvements in yield, quality, and profitability compared to addressing single nutrient deficiencies [4]. - The platform allows advisors to integrate plant tissue data into early season planning and in-season crop management strategies, catering to the needs of specialty crop growers for greater accuracy and confidence in input decisions [5]. Group 3: Features and Accessibility - T.E.A.M. archives historical tissue analysis data, enabling advisors to track nutrient trends over time, which supports informed decision-making and reduces unnecessary applications [6]. - The platform is available for free to pest control advisors and agronomists in the U.S. who work with specialty crops such as tree nuts, tree fruits, berries, and vines [7]. Group 4: Company Background - Balchem Corporation specializes in developing, manufacturing, and marketing specialty ingredients that enhance health and well-being across various industries, with three main business segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products [8].

Company Overview - Balchem Corporation is a leading provider of specialty ingredients and performance products, with over $1.0 billion in trailing twelve-month revenue and a diversified customer base [6] - The company utilizes advanced encapsulation and formulation technologies to deliver differentiated solutions for nutrition, health, and industrial markets [6] - Balchem's product portfolio includes microencapsulated nutrients, food and beverage systems, and sterilization agents, serving various sectors such as food, pharmaceuticals, and animal health [8] Financial Performance - For the year 2025, Balchem reported record net sales of $1 billion, an increase of 8.8%, and net earnings of $154.8 million, up 20.5% [10] - Adjusted EBITDA reached $274.9 million, and free cash flow hit a record $173.6 million [10] - The company maintained a gross margin of 35.6% in the fourth quarter despite input cost pressures [10] Market Position - As of February 17, 2026, Balchem's shares were priced at approximately $180, reflecting an 8% increase over the past year, which is lower than the S&P 500's 16% gain [7] - Balchem represents 1.6% of Harvey Partners' 13F reportable AUM of $1.13 billion, indicating a strategic addition to the fund's portfolio [7] - The company has a solid balance sheet, with cash at $74.6 million and net debt leverage at just 0.3 times adjusted EBITDA [11] Investment Appeal - The addition of Balchem to a portfolio primarily focused on cyclical industrial and equipment names provides a steady compounder with durable growth potential tied to nutrition and health trends [9][12] - The company's strong competitive position within the specialty chemicals sector is supported by its pricing power and recurring demand [12]

Company Overview - Balchem Corporation is a global specialty ingredient manufacturer focused on health and nutrition markets [2] - The company operates through three business segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products [2] - The Human Nutrition & Health segment provides customized food and beverage ingredient systems and key nutrients for food, supplement, and pharmaceutical applications [2] - The Animal Nutrition & Health segment supplies products to various animal health markets [2] - Specialty Products offers specialty-packaged chemicals for healthcare and other industries, as well as chelated minerals for the agricultural market [2] Upcoming Events - Balchem Corporation will participate in the BNP Paribas Exane Consumer Ingredients & Chemicals Conference on March 11, 2026 [1] - Key executives attending the conference include Ted Harris (Chairman, President, and CEO), Martin Bengtsson (CFO), and Allison Baurichter (Senior Director of Investor Relations) [1]

Company Overview - Balchem Corporation is a global specialty ingredient manufacturer focused on health and nutrition markets [2] - The company operates through three business segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products [2] - The Human Nutrition & Health segment provides customized food and beverage ingredient systems and key nutrients for food, supplement, and pharmaceutical applications [2] - The Animal Nutrition & Health segment supplies products to various animal health markets [2] - Specialty Products offers specialty-packaged chemicals for healthcare and other industries, as well as chelated minerals for the micronutrient agricultural market [2] Upcoming Events - Balchem Corporation will participate in the JP Morgan Consumer Ingredients Forum on March 10, 2026 [1] - Key executives attending the conference include Ted Harris (Chairman, President, and CEO), Martin Bengtsson (CFO), and Allison Baurichter (Senior Director of Investor Relations) [1]

Financial Performance - The total backlog as of December 31, 2025, was $53,365, an increase from $50,415 at the end of 2024, with significant contributions from the Human Nutrition and Health (HNH) segment[25]. - Research and development expenses for the year ended December 31, 2025, were approximately $18,510, up from $16,793 in 2024 and $15,049 in 2023, indicating a focus on new product development and improvements[29]. - Capital expenditures in 2025 were approximately $43,193, with investments aimed at expanding capacity and improving process reliability across key product lines[31]. - Capital expenditures are projected to range from $40,000 to $45,000 for 2026, focusing on energy and water-saving projects and exploring renewable energy opportunities[31]. - A 100 basis point increase in interest rates would result in an increase in annual interest expense of approximately $1,640[162]. - The company has exposure to foreign currency exchange risk with a notional amount of $108,569 related to a cross-currency swap[164]. - The company’s borrowings under a revolving loan are subject to fluctuating interest rates based on the consolidated net leverage ratio[162]. Segment Performance - The Animal Nutrition and Health (ANH) segment's choline chloride is essential for poultry and swine health, with the company emphasizing its proprietary chelation technology for enhanced nutrient absorption[17]. - The Human Nutrition and Health (HNH) segment focuses on differentiated products such as specialty vitamin K2 and methylsulfonylmethane (MSM), which are critical for various health applications[16]. - The Specialty Products segment includes performance gases like ethylene oxide and propylene oxide, with a focus on compliance with safety and environmental standards in distribution[20]. - The European Commission imposed definitive duties on choline chloride imports from China, affecting the competitive landscape for the ANH segment[27]. Employee and Operational Metrics - As of December 31, 2025, the company employed approximately 1,352 full-time employees, with a turnover rate of 8% for salaried employees and 23% for hourly employees[41][47]. - The recordable injury rate for the company was 0.63 in 2025, showing improvement from 1.39 in 2023[43]. - The company has been successful in attracting and retaining skilled employees, with approximately 16% covered by collective-bargaining agreements[41]. Environmental and Compliance Efforts - The company is committed to reducing greenhouse gas emissions and global water use through new technologies and operational efficiencies[49]. - The company’s compliance with environmental regulations has not materially affected its operations or financial condition[39]. - The EPA re-registered EtO for sterilization of medical devices and certain spices, with a phase-out period for minor applications and compliance deadlines ranging from several months to ten years[34]. Market and Economic Conditions - The company experienced inflationary pressures in 2025, impacting raw material costs, but has implemented measures to ensure a sustainable supply chain[22]. - The company continues to enhance its technological capabilities to optimize productivity and performance[41]. - The company holds over 130 patents and 400 registered trademarks, leveraging intellectual property to maintain competitive advantages in its product offerings[23].

Financial Data and Key Metrics Changes - For the full year of 2025, the company reported record sales of $1.037 billion, an increase of 8.8% compared to the prior year, marking the first time sales surpassed $1 billion [5] - Record earnings from operations reached $209 million, up 14.4%, and record Adjusted EBITDA was $275 million, an increase of 9.8% from the previous year [5] - Fourth quarter consolidated revenues were $264 million, a 9.8% increase year-over-year, with GAAP earnings from operations at $52 million, up 10.2% [12][13] - Quarterly adjusted EBITDA was $68 million, an increase of 8.1%, and consolidated net income was $39 million, reflecting a 16.8% increase [13][18] Business Segment Data and Key Metrics Changes - The human nutrition and health segment generated sales of $166 million, a 12.7% increase from the prior year, with earnings from operations of $37 million, up 8.9% [19][20] - The animal nutrition and health segment reported quarterly sales of $61 million, a 4.9% increase, with earnings from operations of $6 million, up 8.6% [20][21] - The specialty products segment delivered sales of $35 million, a 6% increase, with earnings from operations of $11 million, up 5.5% [23] Market Data and Key Metrics Changes - The company experienced healthy demand across most end markets, particularly in human nutrition and health, driven by a shift towards nutrient-dense foods [13][14] - The dairy market in animal nutrition remains strong, with modest improvements noted in the European feed-grade choline business following regulatory changes [14][22] Company Strategy and Development Direction - The company continues to focus on geographic expansion, with over half of sales growth in 2025 coming from markets outside the United States [8][74] - Strategic partnerships, such as those with the New York Jets and Bayern Munich women's soccer team, have been successful in promoting key brands and expanding market reach [9][33] - The company is committed to sustainability goals, having reduced greenhouse gas emissions by approximately 31% compared to the 2020 baseline [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate macroeconomic challenges and maintain growth momentum [24] - The outlook for 2026 is positive, with expectations for continued top and bottom-line growth while advancing strategic initiatives [24] Other Important Information - The company generated record free cash flow of $174 million in 2025 and invested $43 million in capital projects [6] - A dividend increase from $0.87 to $0.96 per share was announced, marking the 17th consecutive year of double-digit growth [11][12] Q&A Session Summary Question: Discussion on the partnership with the New York Jets - Management highlighted the successful partnership, which has shifted the narrative around the importance of choline for adult health, leading to increased adoption in various products [29][33] Question: Planned sales and promotional activities for 2026 - The company plans to enhance marketing efforts through social media and digital marketing, alongside existing partnerships [45][50] Question: Impact of the Supreme Court decision on tariffs - Management indicated that the company is well-positioned to manage potential disruptions from tariff changes, with a manageable impact previously estimated at around $10 million [46][49] Question: Update on international sales growth - The company is seeing improved volumes and pricing dynamics in Europe following regulatory changes, with a focus on expanding international market presence [70][74]

Financial Data and Key Metrics Changes - For the full year of 2025, the company reported record sales of $1.037 billion, an increase of 8.8% compared to the prior year, marking the first time sales surpassed $1 billion [5] - Record earnings from operations reached $209 million, up 14.4%, and record Adjusted EBITDA was $275 million, an increase of 9.8% from the previous year [5] - Q4 consolidated revenues were $264 million, a 9.8% increase year-over-year, with GAAP earnings from operations of $52 million, up 10.2% [12][13] - Q4 Adjusted EBITDA was $68 million, an increase of 8.1%, with a net income of $39 million, reflecting a 16.8% increase [13][18] Business Segment Data and Key Metrics Changes - The Human Nutrition and Health segment generated sales of $166 million, a 12.7% increase from the prior year, with earnings from operations of $37 million, up 8.9% [19][20] - The Animal Nutrition and Health segment reported sales of $61 million, a 4.9% increase, with earnings from operations of $6 million, up 8.6% [20][21] - The Specialty Products segment delivered sales of $35 million, a 6% increase, with earnings from operations of $11 million, up 5.5% [23] Market Data and Key Metrics Changes - More than half of the sales growth in 2025 came from markets outside the United States, indicating a strong international demand [8] - The dairy market remains healthy, particularly for dairy protein, while the European market for feed-grade choline has shown modest improvement following anti-dumping duties [14][22] Company Strategy and Development Direction - The company continues to invest in strategic growth priorities, including expanding sales and marketing reach both domestically and internationally [8] - Significant investments were made in plant and equipment to support growth, including a new microencapsulation manufacturing facility [10] - The company aims to reduce greenhouse gas emissions and water usage by 25% by 2030, having already surpassed its 2030 goal for emissions reduction [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate macroeconomic challenges and maintain growth momentum [24] - The company is well-positioned to deliver continued top and bottom-line growth in 2026, supported by strong competitive positions and a differentiated product portfolio [24] Other Important Information - The company repurchased approximately 685,000 shares at an average cost of $158 per share, marking a commitment to returning capital to shareholders [11] - The annual dividend was increased from $0.87 to $0.96 per share, representing a 10% year-over-year increase [11][12] Q&A Session Summary Question: Discussion on the partnership with the New York Jets - Management highlighted the successful partnership, which has helped change the dialogue around the importance of choline for adult health, leading to increased adoption in various products [29][30] Question: Planned sales and promotional activities for 2026 - The company plans to continue its partnerships with the Jets and Bayern Munich, while also increasing social media and digital marketing efforts [45][51] Question: Impact of the Supreme Court decision on tariffs - Management expressed confidence in managing potential disruptions, noting that the theoretical impact of tariffs was manageable and that they have strategies in place to mitigate risks [46][48] Question: Update on international growth and pricing dynamics in Europe - Management confirmed improvements in Europe following the final ruling on anti-dumping duties, with increased volumes and firming prices expected [71][72]

Financial Data and Key Metrics Changes - For the full year of 2025, the company reported record sales of $1.037 billion, an increase of 8.8% compared to the prior year, marking the first time sales surpassed $1 billion [5] - Record earnings from operations reached $209 million, up 14.4%, and record Adjusted EBITDA was $275 million, an increase of 9.8% from the previous year [5] - Fourth quarter consolidated revenues were $264 million, a 9.8% increase year-over-year, with GAAP earnings from operations of $52 million, up 10.2% [12][13] - Quarterly adjusted EBITDA was $68 million, an increase of 8.1%, with consolidated net income at $39 million, up 16.8% [13][18] Business Segment Data and Key Metrics Changes - The human nutrition and health segment generated sales of $166 million, a 12.7% increase from the prior year, with earnings from operations of $37 million, up 8.9% [19][20] - The animal nutrition and health segment reported sales of $61 million, a 4.9% increase, with earnings from operations of $6 million, up 8.6% [20][21] - The specialty products segment delivered sales of $35 million, a 6% increase, with earnings from operations of $11 million, up 5.5% [22][23] Market Data and Key Metrics Changes - More than half of the sales growth in 2025 came from markets outside the United States, indicating a strong international demand [8] - The dairy market remains healthy, particularly for dairy protein, while modest improvements were noted in the European feed-grade choline market following anti-dumping duties [14][21] Company Strategy and Development Direction - The company continues to invest in strategic growth priorities, including expanding sales and marketing reach both domestically and internationally [8][10] - Significant investments were made in plant and equipment to support growth, including a new microencapsulation manufacturing facility in New York State [10][11] - The company is focused on maintaining a strong balance sheet while returning capital to shareholders through share repurchases and dividend increases [11][12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate macroeconomic challenges and maintain growth momentum [24] - The company anticipates continued top and bottom-line growth in 2026, supported by strong competitive positions and a differentiated product portfolio [24] Other Important Information - The company achieved a net debt reduction to $89 million, with a leverage ratio of 0.3 [19] - The annual dividend was increased from $0.87 to $0.96 per share, marking the 17th consecutive year of double-digit growth [11][12] Q&A Session Summary Question: Discussion on the partnership with the New York Jets - Management highlighted the successful partnership, which has shifted the dialogue around the importance of choline for adult health, leading to increased adoption in various products [30][34] Question: Updates on clinical trials and their potential impact - Management confirmed ongoing clinical trials, with several expected to conclude in 2026, which could lead to new sales opportunities based on positive results [38][39] Question: Planned sales and promotional activities for 2026 - The company plans to enhance marketing efforts through social media and digital marketing, alongside existing partnerships with professional sports teams [49][50] Question: Impact of recent tariff decisions - Management expressed confidence in managing potential disruptions from tariff changes, noting that previous impacts were manageable and the company is well-positioned [46][48] Question: Effective tax rate assumptions - The effective tax rate is expected to be around 23% for modeling purposes, consistent with previous years [52] Question: International growth and pricing dynamics in Europe - Management reported improvements in European markets following recent regulatory changes, with expectations for continued growth in both volume and pricing [70][72][75]

Investor Presentation Q4 2025. Safe Harbor Statement 2 Financial Performance 04 & Capital Allocation • During the course of this presentation, management may make forward-looking statements regarding financial performance and future events. • These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "forecast," "outlook," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," ...